These ASX shares are having very positive days…
The post Why Accent, Calix, Pilbara Minerals, & Starpharma shares are racing higher appeared first on The Motley Fool Australia. –
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is off its lows but still in the red. At the time of writing, the benchmark index is down 0.2% to 7,422.7 points.
Four ASX shares that are not letting that hold them back are listed below. Here’s why they are racing higher:
Accent Group Ltd (ASX: AX1)
The Accent share price has jumped 11.5% to $2.29. Investors have been buying the footwear retailer’s shares after Morgan Stanley upgraded them to an overweight rating with a $2.60 price target. The broker made the move partly on the belief that the company will open more stores than forecast in FY 2022. It also sees opportunities for its store network to expand internationally in the future.
Calix Ltd (ASX: CXL)
The Calix share price has rocketed 37% higher to $5.26. Investors have been buying the new materials company’s shares after Carbon Direct invested US$15 million into one of its subsidiaries. As part of the deal, Calix has entered into a licence agreement that will earn it royalties from the deployment of its technology.
Pilbara Minerals Ltd (ASX: PLS)
The Pilbara Minerals share price is up 8.5% to $2.45. Investors have been buying the lithium miner’s shares after it released the results of its second lithium spodumene concentrate digital auction. According to the update, Pilbara Minerals received a bid of US$2,240/dmt for 8,000 dmt of its spodumene concentrate. This was almost double what it received at its inaugural auction last month.
Starpharma Holdings Limited (ASX: SPL)
The Starpharma share price is up 5% to $1.38. This morning the dendrimer products developer announced that it has been granted a new US patent in relation to DEP cabazitaxel. The release notes that the composition of matter patent builds on Starpharma’s suite of existing international DEP patents for the product. It specifically covers a DEP dendrimer conjugated to multiple cabazitaxel drug molecules via a particular releasable linker.
The post Why Accent, Calix, Pilbara Minerals, & Starpharma shares are racing higher appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of August 16th 2021
Starpharma (ASX:SPL) share price surges 5% on United States patent news
There are the 3 most traded ASX 200 shares so far today
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Accent Group and Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.